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The twentieth century witnessed the birth 
of the medical discipline of Radiation 
Oncology, beginning with the discovery 
and clinical application of radium in the 
early 1900s. Subsequently, clinical radia-
tion oncology evolved as a major modal-
ity for the treatment of most solid cancers 
with the initial use of orthovoltage x-rays, 
to the use of supervoltage photons and 
electrons and, most recently, to the use 
of neutrons, protons, and other charged 
particles. In the last quarter of the century, 
Radiation Oncology readily adapted and 
integrated the use of supercomputers and 
new imaging modalities (CT, MRI, PET/
CT) into radiation treatment planning and 
delivery to transition from 2-dimensional 
(2-D) to 3-D, and now to 4-D treatment. 
As we moved through the first decade of 
the twenty-first century, our ability to care-
fully conform the radiation dose to the 
outlines of irregularly shaped tumor or 
target volumes while also creating a steep 
radiation dose gradient to adjacent normal 
tissues is now becoming standard-of-care 
with the use of image-guided and inten-
sity-modulated radiation therapy (IGRT 
and IMRT, respectively) or with the use 
of stereotactic radio surgery (SRS). This 
rapid evolution in imaging and radiation 
treatment technologies was only made 
possible by the simultaneous integration 
of specialty trained medical physicists 
and dosimetrists as essential members of 
Radiation Oncology departments.
The latter half of the twentieth century 
also witnessed the development of radiation 
biology as an essential basic-translational 
component of Radiation Oncology. With 
the overall goal of better understanding the 
acute and late side effects of ionizing radia-
tion (IR) on both malignant and normal 
cells/tissues, five major biologic concepts 
have emerged from these research efforts 
that currently influence clinical radiation 
oncology. These concepts (the so-called “5 
R’s”) include: intrinsic cellular radiosensi-
tivity; acute/chronic hypoxia and reoxy-
genation; differential DNA damage-repair 
processing; cell cycle redistribution; and 
tumor cell repopulation. When combined 
with today’s sophisticated 3-D and 4-D 
radiation treatment planning/delivery, the 
radiation oncologist attempts to interpolate 
the 5-R concepts into clinical practice for 
a particular tumor in a particular patient 
so as to maximize the therapeutic index 
(TI). However, since few cancers are now 
treated with radiation therapy as a single 
modality, determination of the maximum 
TI is complicated by the spatial and tem-
poral interactions of radiation therapy 
with surgery, conventional chemotherapy, 
and newer biologics/small molecules. As 
such, close interactions amongst radiation 
oncologists, surgeons, and medical oncol-
ogists are clearly needed today and more 
so in the future as we attempt to improve 
the “complication-free” cure rates in cer-
tain cancers or to provide more effective 
and less toxic palliative treatment in other 
cancers. With newer combined modality 
approaches, treatment of some cancers as 
chronic diseases involving effective treat-
ment of limited metastatic disease will be 
an emerging area for clinical research in 
Radiation Oncology.
Looking back over the last one to two 
decades, one can conclude that few medi-
cal disciplines have undergone such rapid 
change in treatment concepts and technolo-
gies as Radiation Oncology. However, look-
ing ahead, many, many (Grand) challenges 
remain, particularly as we enter the era of 
“personalized” cancer therapy. As part of 
this introduction to Frontiers of Radiation 
Oncology, I will briefly describe three such 
challenges.
One major challenge for Radiation 
Oncology in the near future will be to 
broaden the current cross-disciplinary team 
of radiation oncologists, medical physicists, 
and radiation biologists to include engi-
neers and mathematicians in a systems 
science/biology approach. The recent devel-
opment of more cost–effective technolo-
gies to comprehensively assess DNA, RNA, 
protein, and metabolites in patients’ tumors 
provides opportunities to tailor cancer care. 
We currently have validated molecular tests 
in breast and colorectal cancers which drive 
chemotherapy decision making. Is the radi-
ation-chip on the horizon?
The promise of personalized radiation 
therapy will necessitate overcoming many 
theoretical and regulatory challenges. 
The new high-throughput technologies 
of genomics, proteinomics, and metabo-
lomics when applied to patients’ tumor 
or blood samples results in huge masses 
of data which are challenging to manage, 
visualize, and then convert to knowledge in 
a meaningful way to impact patients’ tumor 
responses and/or normal tissue toxicities. 
A cross-disciplinary integrated systems 
biology approach involving engineering, 
physics, and mathematics with biological 
and medical insights will be necessary to 
convert the information from these multidi-
mensional data sets into useful biomarkers 
to predict tumor response to treatment and 
to identify the key drivers (genes, proteins, 
metabolites) of tumor behavior that are 
potential targets for therapy. Such a sys-
tems understanding of the effects of tar-
geted therapeutics (i.e., small molecules and 
biologics combined with radiation therapy) 
on signaling networks and homeostatic 
regulatory loops on tumor and normal 
tissues will be necessary to prevent exces-
sive normal tissue toxicities and to develop 
more rational combinatorial therapies with 
radiation including the emerging treatment 
paradigm of synthetic lethality.
Over the last 5–10 years, the pre-clini-
cal scientific literature has defined several 
molecular signaling pathways (or networks) 
which are activated by IR and which are 
potentially amenable to targeted therapies 
with biologics and/or small molecule inhibi-
tors for tumor radiosensitization and, less 
commonly, for normal tissue radioprotec-
tion. Many of these potential targets have 
emerged from our improved understanding 
of the DNA damage and repair pathways. 
For example, in my inaugural article for 
Frontiers in Radiation Oncology, I describe 
in detail the results of several pre-clinical 
studies involving radiation biology and 
systems science approaches to enhance Frontiers in Oncology | Radiation Oncology    May 2011  | Volume 1  |  Article 7  |  2
Kinsella  Future challenges for radiation oncology
More likely is the scenario where tumor and 
normal tissue biology changes during treat-
ment and, as such, adaptive radiotherapy 
will be necessary to truly impact on the TI. 
The implementation of adaptive radiother-
apy will require the development of newer 
functional imaging (MRI, MRS, PET) to 
monitor temporal and spatial variations in 
tumor radiation response and normal tissue 
function during the course of treatment.
Finally, in the era of medical cost con-
tainment for all medical fields, but espe-
cially for a high-tech discipline such as 
Radiation Oncology, we will need to develop 
new quantitative measures of comparative 
effectiveness. With our aging population in 
all parts of the world and the emergence of 
new forms of cancer (e.g., HPV-associated 
head and neck cancer), actuarial projections 
of the cancer burden may double over the 
next few decades. Toward this end, the dis-
cipline of Radiation Oncology must accept 
the challenge of making our treatment 
approaches more cost–effective while also 
striving to enhance the TI.
While I cite only three major challenges 
for the near future of Radiation Oncology, 
I know that there will be many others. With 
the support of the Editorial Board and the 
entire Radiation Oncology community, 
Frontiers of Radiation Oncology will be a 
major forum for addressing these and other 
future challenges. Welcome to the new jour-
nal and this new style of publishing!
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dosing schedules when combined with 
  conventional or altered fractionated radia-
tion therapy. Both of these challenges are 
multi-faceted. By definition, the target must 
be present in the tumor with sufficient dif-
ferential expression from dose-limiting 
normal tissues to allow for an increased TI 
(or simply to maintain a TI). Currently, we 
do not have readily accessible diagnostics 
to provide molecular confirmation of the 
intended target nor available biomark-
ers (serum levels, imaging studies, etc.) to 
monitor the specificity of tumor targeting 
during treatment. While we can “image” 
hypoxia, for example, we cannot then simul-
taneously measure the effects of hypoxia 
on altering angiogenesis, DNA repair, or 
cellular metabolism. Given these current 
realities with respect to the integration of 
targeted therapies and radiation therapy, the 
overall challenge for the radiation oncology 
community in the future will be to begin to 
carefully design clinical trials with appro-
priate biomarker assessments for tumor 
and normal tissues. Hopefully, Frontiers in 
Radiation Oncology will provide a major 
forum for discussing the future successes 
(and failures) of such clinical trials as well 
as discussing new leads for targeted therapy 
using pre-clinical experimental models.
A second major challenge for Radiation 
Oncology will be to integrate the new 
insights on tumor and normal tissue radio-
biology into a dynamic time-sensitive and 
spatial-sensitive treatment plan. Even with 
“sophisticated” IMRT and IGRT treatment 
planning and delivery, we assume that both 
tumor radiation sensitivity and normal 
tissue function are uniformly distributed 
within their respective volumes. We also 
assume that a particular patient’s tumor 
and normal tissue radiobiological charac-
teristics do not change during a several week 
course of radiation therapy. Unfortunately, 
both assumptions are probably wrong. 
 iododeoxyuridine-mediated  radiosensiti-
zation in DNA mismatch repair deficient 
(damage-tolerant) human cancers. Other 
potential direct modifiers of key signal-
ing pathways involved in IR-induced DNA 
damage/repair include the use of biolog-
ics or small molecular inhibitors or ATM, 
DNA-PKcs, PARP, and DNA polymerases. 
Such modifiers can lead to increased resid-
ual IR-induced DNA strand breaks (both 
DSBs and SSBs) in tumor, and ideally less 
in irradiated normal tissues, to maintain 
a TI. Other direct modifiers of p53 and 
the cyclin dependent kinases, Chk1 and 
Chk2, have been shown experimentally to 
abrogate the G1 and G2/M IR-induced cell 
cycle checkpoints, also leading to increased 
unrepaired SSBs and DSBs and enhanced 
IR cytotoxicity.
The pre-clinical scientific literature has 
also designated the tumor microenviron-
ment for potential IR-mediated targeted 
therapy. Acute and/or chronic hypoxia and 
a lowered (acidic) pH in the microenviron-
ment result in tumor-associated alterations 
in cellular metabolism, angiogenesis, and 
genetic (DNA repair) stability. As such, 
newer targeted therapy attempting to target 
anaerobic glycolysis or tumor vasculature 
can also potentially enhance IR cytotoxic-
ity. Finally, tumor targeted therapy using 
IR-inducible gene vectors offers a poten-
tial indirect approach to enhance tumor 
response through modification of a local 
immune (e.g., TNF release) pathway.
However, there are many translational 
challenges for the radiation oncology com-
munity involved in applying these exciting 
experimental findings to the clinic. In addi-
tion to the issues of the pharmacokinetics 
and pharmacodynamics of these biologics 
and small molecules, two of the greatest 
translational challenges involve the selec-
tion of appropriate patient/tumor groups 
and the determination of the optimal 